Home > Letter from the Editor

Letter from the Editor

Prof. Hans-Peter Hartung, Heinrich-Heine-University, Germany
EAN 2020
Dear colleagues,

The 6th Congress of the European Academy of Neurology (EAN) was supposed to be held in Paris May 23-May 26, 2020. In the wake of the COVID-19 pandemic, like many other congresses before and after, with little preparation the meeting had to go virtual.

More than 42,500 neurologists registered for this virtual event that highlighted research from all areas of neurology. In response to the COVID-19 pandemic, very recent data were presented on an EAN survey on neurological symptoms. The EAN also has set up a neuroCOVID registry to gather information on clinical characteristics, management, and outcome.

This report tries to provide an overview of the most relevant contributions presented at EAN virtual 2020.

Professor and Chairman 



Prof. Hartung has been chair of the Department of Neurology at Heinrich Heine University Düsseldorf since 2001. He was also appointed director of the Center for Neurology and Neuropsychiatry in 2012 and Medical Director of the Department of Conservative Medicine.

Prof. Hartung received his undergraduate training at the Universities of Düsseldorf, Glasgow, Oxford, and London. After graduating magna cum laude he served an immunology fellowship at the University of Mainz. His clinical and translational research interests are in the field of basic and clinical neuroimmunology and in particular multiple sclerosis and immune neuropathies.

He has been involved as member of the Steering Committee in numerous international multicentre therapeutic phase 2 and 3 trials in Multiple Sclerosis, Guillain-Barré Syndrome, and chronic inflammatory demyelinating polyneuropathy.

He is former President of ECTRIMS and is a Fellow of the American Academy of Neurology, Fellow and general assembly member of the EAN, has been chair/member of the management group of the EAN scientific panels on general neurology and multiple sclerosis, amongst others. He is/was also member of the Editorial Board of a number of international journals.

Conflict of Interest Statement:

Hans-Peter Hartung has received fees for consulting, speaking, and serving on steering committees from Bayer Healthcare, Biogen, GeNeuro, MedImmune, Merck, Novartis, Opexa, Receptos Celgene, Roche, Sanofi Genzyme, CSL Behring, Octapharma, Teva, TG Therapeutics, and Viela Bio, with approval by the Rector of Heinrich-Heine-University.

Posted on